The emergence of biologics that inhibit IL-17 has provided new avenues in the maintenance therapy of many autoimmune diseases [8], in which secukinumab has proven efficacy in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Here, IL17A is linked to ankylosing spondylitis.